<style face="normal" font="default" size="100%">729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors</style>

Drupal-HighWire